Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Xiaogan Wang"'
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundTeduglutide, the first glucagon-like peptide 2 analogue, has been demonstrated to facilitate the absorption of gut nutrient and lessen the need for parenteral assistance in patients with Short Bowel Syndrome (SBS). However, its adverse drug
Externí odkaz:
https://doaj.org/article/defbf70cd2684e7eac9eaf178e50f167
Autor:
Hongye Gao, Xiaogan Wang, Yumei Lai, Chen Zhang, Lan Mi, Xinqiang Ji, Xiaopei Wang, Yuqin Song, Jun Zhu, Weiping Liu
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8038-8049 (2023)
Abstract Background To our knowledge, the different situations of identifying second primary malignant tumors (SPMTs) in lymphoma patients with synchronous solid tumors remain to be comprehensively investigated. Methods We retrospectively collected i
Externí odkaz:
https://doaj.org/article/5e275be686784d02b2ca41731e989af5
Autor:
Jiao Li, Hui Yu, Xing Wang, Yingying Ye, Wei Fang, Ning Ding, Lan Mi, Lingyan Ping, Xiaogan Wang, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Control, Vol 29 (2022)
Introduction Mantle cell lymphoma (MCL) is an aggressive and incurable B-cell-derived malignant disease. MCL is treated using general chemotherapy; however, disease progression and relapse are common; thus, the development of novel therapeutic target
Externí odkaz:
https://doaj.org/article/2de18553482942c29a515087f0ee1fa5
Autor:
Hui Yu, Xing Wang, Jiao Li, Yingying Ye, Dedao Wang, Wei Fang, Lan Mi, Ning Ding, Xiaogan Wang, Yuqin Song, Jun Zhu
Publikováno v:
Molecular Therapy: Oncolytics, Vol 21, Iss , Pp 158-170 (2021)
Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials
Externí odkaz:
https://doaj.org/article/2d7c4c8f1e084e51b9b24dbb5c09d3ca
Autor:
Yalu Liu, Xiaogan Wang, Lijuan Deng, Lingyan Ping, Yunfei Shi, Wen Zheng, Ningjing Lin, Xiaopei Wang, Meifeng Tu, Yan Xie, Weiping Liu, Zhitao Ying, Chen Zhang, Zhengying Pan, Xi Wang, Ning Ding, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Cell International, Vol 19, Iss 1, Pp 1-19 (2019)
Abstract Background Angioimmunoblastic T cell lymphoma (AITL) is a distinct subtype of peripheral T cell lymphoma and associated with poor outcomes. The activation status of T cell receptor (TCR) signaling has recently become a focus of attention in
Externí odkaz:
https://doaj.org/article/25c3629a1d384e438702a199c33a1a2e
Autor:
Yizi He, Jiao Li, Ning Ding, Xiaogan Wang, Lijuan Deng, Yan Xie, Zhitao Ying, Weiping Liu, Lingyan Ping, Chen Zhang, Yuqin Song, Jun Zhu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-16 (2019)
Abstract Background Diffuse large B cell lymphoma (DLBCL) is the most common form of lymphoma. Although durable remissions can be achieved in more than half of these patients, DLBCL remains a significant clinical challenge, with approximately 30% of
Externí odkaz:
https://doaj.org/article/0c21c9711cd44ef292c51b467964b40d
Autor:
Cunzhen Shi, Xiangqun Li, Xiaogan Wang, Ning Ding, Lingyan Ping, Yunfei Shi, Lan Mi, Yumei Lai, Yuqin Song, Jun Zhu
Publikováno v:
Journal of Hematology & Oncology, Vol 11, Iss 1, Pp 1-13 (2018)
Abstract Background Mantle cell lymphoma (MCL) is an incurable B cell-derived malignant tumor with a median overall survival of 4–5 years. Mer tyrosine kinase (MerTK) has been reported to be aberrantly expressed in leukemia, melanoma, and gastric c
Externí odkaz:
https://doaj.org/article/15fcd2c9ed7844c09ee285adf7d3c3e6
Autor:
Yalu Liu, Xiaogan Wang, Ning Ding, Lan Mi, Lingyan Ping, Xuan Jin, Jiao Li, Yan Xie, Zhitao Ying, Weiping Liu, Chen Zhang, Lijuan Deng, Yuqin Song, Jun Zhu
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-7 (2017)
Abstract Background TP53 Arg72Pro (SNP rs1042522) is associated with risk of non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL. However, the relationship between this SNP and prognosis of DLBCL in Asi
Externí odkaz:
https://doaj.org/article/dae9bec12f6e47558aa40143fa73e5b8
Autor:
Jiao Li, Ning Ding, Xiaogan Wang, Lan Mi, Lingyan Ping, Xuan Jin, Yalu Liu, Zhitao Ying, Yan Xie, Weiping Liu, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Cell International, Vol 17, Iss 1, Pp 1-7 (2017)
Abstract Background Rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) is used as standard frontline regimen for diffuse large B-cell lymphoma (DLBCL). The landscape of somatic mutations in DLBCL revealed that in
Externí odkaz:
https://doaj.org/article/9335fcae56254c0398b049ccc2a6b0f0
Autor:
Hui Yu, Lan Mi, Weimin Zhang, Yingying Ye, Miaomiao Li, Dingyao Hu, Jiaowu Cao, Dedao Wang, Xiaogan Wang, Ning Ding, Yuqin Song, Jun Zhu
Publikováno v:
Hematological Oncology. 40:894-905
Aberrant activity of histone deacetylases (HDACs) is frequently detected in B-cell lymphomas, which indicated the therapeutic implications of HDAC inhibitors for B-cell malignancies. We have discovered that lymphoma cells treated with HDAC inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce18ccb61162056612ba910a00a41a73
https://doi.org/10.1002/hon.3056
https://doi.org/10.1002/hon.3056